Germany-based CRO continues expansion in US

By Melissa Fassbender contact

- Last updated on GMT

The Massachusetts Biotechnology Council was founded in 1985. (Image: Getty/GrandviewGraphics)
The Massachusetts Biotechnology Council was founded in 1985. (Image: Getty/GrandviewGraphics)
KCR has joined the Massachusetts Biotechnology Council – a “must” for the CRO as it continues to strengthen its footprint in the US market, says CEO.

The Germany-based contract research organization​ (CRO) moved to a new office in Boston earlier this year, at which time KCR CEO, Mike Jagielski, told us​: “Boston is where money and research meet on the East coast​.”

Jagielski said joining the Massachusetts Biotechnology Council (MassBio) – a not-for-profit organization that represents and provides services to life sciences companies – was a natural step for KCR and a “must​” following the recent move to Boston.

KCR has been present on the US market for a few years​,” he told us. “We have been delivering services in the US for some time, but we were missing an office to focus more pro-actively on growing our US business​.”

The CRO also has operation's hubs in Berlin, Kiev, and Warsaw.

Since our office opening in Boston we are building a strong team to manage full-service delivery in the US and connect us effectively with the European operations for US/Europe projects​,” Jagielski added.

Related news

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers